Advances and Challenges of Liposome Assisted Drug Delivery

Sercombe, Lisa; Veerati, Tejaswi; Moheimani, Fatemeh; Wu, Sherry Y.; Sood, Anil K.; Hua, Susan

doi:10.3389/fphar.2015.00286

Cited by 1,937 publications

(1,469 citation statements)

References 113 publications

Supporting

Mentioning

1,319

Contrasting

Unclassified

Order By: Relevance

“…However, these bilayer and acyl‐chain lipid products have not fulfilled their practical potential due to their insufficient morphological stability and inclusion leakage in vitro and in vivo 9. To address these drawbacks, various optimizations have been approached,10 which include surface coating with certain amphiphilic molecules (PEGylation; where PEG is polyethylene glycol) and cholesterols for prolonging circulation,11 enhancing elasticity using transferosome formulations for transdermal delivery,12 and improving bioavailability that employ drug–lipid conjugates 13. Although these strategies have significantly promoted the therapeutic potential of traditional lipid nanoparticles with increasingly broad applications, several concerns such as insufficient coverage of surface coating on phospholipid bilayers,14 and the morphological stability of lipid assemblies are likely to decrease after modulating composition, charge, and bilayer architecture.…”

Section: Introductionmentioning

confidence: 99%

Advancing the Pharmaceutical Potential of Bioinorganic Hybrid Lipid‐Based Assemblies

Wang

et al. 2018

Advanced Science

View full text Add to dashboard Cite

Bioinspired lipid assemblies that mimic the elaborate architecture of natural membranes have fascinated researchers for a long time. These lipid assemblies have gone from being just an imperative platform for biophysical research to a pharmaceutical delivery system for biomedical applications. Despite success, these organized nanosystems are often subject to the mechanical instability and limited theranostic capability without adding any inconvenient modifications. To reach their advanced pharmaceutical potential, various bioinorganic hybrid lipid‐based assembles, which provide new opportunities to synergistically complement and improve therapeutic/diagnostic potential of existing lipid‐based nanomedicine with distinct mechanisms containing inorganic embedded surfactants, have recently been developed.

show abstract

Section: Introductionmentioning

confidence: 99%

Advancing the Pharmaceutical Potential of Bioinorganic Hybrid Lipid‐Based Assemblies

Wang

et al. 2018

Advanced Science

View full text Add to dashboard Cite

show abstract

“…The field of theranostics in cancer therapy has rapidly expanded over the past decade, seeking the 'holy grail' of delivery of significant concentrations of drug to target tissues (either a chemotherapeutic agent or imaging tracer) with high specificity and minimal off-target effects, with the goals of increasing therapeutic index (Sercombe et al 2015). Nanoliposomes offer a well-studied and attractive model for drug delivery and can deliver large payloads per particle.…”

Section: :6mentioning

confidence: 99%

“…Nanoliposomes offer a well-studied and attractive model for drug delivery and can deliver large payloads per particle. Organ-specific targeting and immune system evasion can be modulated by molecules embedded in the lipid bilayer (Sercombe et al 2015).…”

Section: :6mentioning

confidence: 99%

Targeting the TSH receptor in thyroid cancer

Rowe¹,

Paul²,

Gedye³

et al. 2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.

show abstract

“…4,5 Polymer-based nanoparticles (NPs) also present low toxicity, but their surface functionalization may affect their safety. The most commonly used materials include PEG, ploy(lactic-co-glycolic) acid (PLGA), polylactic acid (PLA), and polycaprolactone (PCL).…”

mentioning

confidence: 99%

“…3 Because of high biocompatibility of lipids, several commercial liposome-drug formulations have been developed, mostly relying on polyethylene glycol (PEG)-conjugated lipids, such as DOXIL, AmBisome, Epaxal, and Inflexal V, and are under clinical trials focusing on various types of disease treatments. 4,5 Polymer-based nanoparticles (NPs) also present low toxicity, but their surface functionalization may affect their safety. The most commonly used materials include PEG, ploy(lactic-co-glycolic) acid (PLGA), polylactic acid (PLA), and polycaprolactone (PCL).…”

mentioning

confidence: 99%

Facilitating Translational Nanomedicine via Predictive Safety Assessment

et al. 2017

View full text Add to dashboard Cite

Extensive research on engineered nanomaterials (ENMs) has led to the development of numerous nano-based formulations for theranostic purposes. Although some nano-based drug delivery systems already exist on the market, growing numbers of newly designed ENMs exhibit improved physicochemical properties and are being assessed in preclinical stages. While these ENMs are designed to improve the efficacy of current nanobased therapeutic or imaging systems, it is necessary to thoroughly determine their safety profiles for successful clinical applications. As such, our aim in this mini-review is to discuss the current knowledge on predictive safety and structure-activity relationship (SAR) analysis of major ENMs at the developing stage, as well as the necessity of additional long-term toxicological analysis that would help to facilitate their transition into clinical practices. We focus on how the interaction of these nanomaterials with cells would trigger signaling pathways as molecular initiating events that lead to adverse outcomes. These mechanistic understandings would help to design safer ENMs with improved therapeutic efficacy in clinical settings.During the past decades, engineered nanomaterials (ENMs) have been widely used in biomedical applications, such as nanomedicine, bioimaging, and tissue engineering, because of their unique biophysicochemical properties.1,2 With regard to nanomedicine applications, ENMs could be formulated as drug carriers that deliver the therapeutic reagents within the human body and increase their bioavailability and blood circulation half-life.2 Moreover, these nanocarriers could be functionalized to deliver the drug specifically to the desired target tissues (e.g., tumors) and release the payload sustainably over long periods, thereby eliminating the necessity of multiple drug administration and reducing its cytotoxic side effects toward healthy cells.2 In addition to their implementation in drug delivery, ENMs could be used for diagnostic and imaging purposes that would help to monitor the disease and administer the treatment more accurately. 2Past research in nanomedicine has led to the design of various nanomaterial-based therapeutic and diagnostic systems that are being investigated in experimental stages (e.g., in vitro and in vivo) and clinical trials or are commercially available to the corresponding patients (Table 1). Most commercialized nanomaterial-based therapeutic reagents use lipids, proteins, and polymers that could self-assemble and biodegrade with few side effects.3 Because of high biocompatibility of lipids, several commercial liposome-drug formulations have been developed, mostly relying on polyethylene glycol (PEG)-conjugated lipids, such as DOXIL, AmBisome, Epaxal, and Inflexal V, and are under clinical trials focusing on various types of disease treatments. 4,5 Polymer-based nanoparticles (NPs) also present low toxicity, but their surface functionalization may affect their safety. The most commonly used materials include PEG, ploy(lactic-co-glycolic) acid (PLGA...

show abstract

Advances and Challenges of Liposome Assisted Drug Delivery

Cited by 1,937 publications

References 113 publications

Advancing the Pharmaceutical Potential of Bioinorganic Hybrid Lipid‐Based Assemblies

Advancing the Pharmaceutical Potential of Bioinorganic Hybrid Lipid‐Based Assemblies

Targeting the TSH receptor in thyroid cancer

Facilitating Translational Nanomedicine via Predictive Safety Assessment

Contact Info

Product

Resources

About